To evaluate the factors influencing the effect of the intravitreal bevacizumab injection in patients with central serous chorioretinopathy.

We performed a retrospective review of the medical records of 54 patients (56 eyes) who had been symptomatic for more than 3 months with central serous chorioretinopathy (CSC), who had undergone intravitreal bevacizumab injection and been on regular follow-up for at least 6 months.

Responders were 34 eyes (60.7%) and non-responders were 22 eyes (39.3%). The leaking points of the non-responder group were multiple and located more centrally than that of the responder group on fluorescein angiography (FA) ( p = 0.01, p = 0.044). In addition, non-responder group showed cystoid macular edema on optical coherence tomography (OCT) as compared with responder group ( p = 0.042).

CSC with multiple, centrally located leaks on FA or cystoid macular edema on OCT was ineffective or recurrent with intravitreal bevacizumab injection.